General Information of Drug (ID: DMU263R)

Drug Name
VBY-376 Drug Info
Synonyms Protease inhibitor (hepatitis C virus infection), Virobay
Indication
Disease Entry ICD 11 Status REF
Hepatitis C virus infection 1E51.1 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMU263R

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GS-9451 DMF910Q Chronic HCV-1 infection 1E51.1 Phase 2 [3]
GS-9857 DMYU6P5 Hepatitis C virus infection 1E51.1 Phase 2 [4]
BILN-2061 DM2J36F Hepatitis virus infection 1E50-1E51 Phase 2 [5]
ACH-2684 DMW6X0O Hepatitis C virus infection 1E51.1 Phase 1 [6]
BMS-605339 DMY7ZRA Hepatitis C virus infection 1E51.1 Terminated [7]
GNF-PF-3464 DMWAKHD Discovery agent N.A. Investigative [8]
AcAsp-D-Gla-Leu-Ile-Cha-Cys DMT74F5 Discovery agent N.A. Investigative [9]
Cbz-Ile-Leu-L-(difluoro)aminobutyric acid DMI53WR Discovery agent N.A. Investigative [9]
AcGlu-Dif-Ile-Cha-Cys DMK6HGI Discovery agent N.A. Investigative [10]
AcGlu-Dif-Glu-Cha-Cys DM0BV9I Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Hepatitis C virus NS3 helicase (HCV NS3) TTWXB3E POLG_HCV1 Inhibitor [2]

References

1 ClinicalTrials.gov (NCT00557583) Evaluation of Safety and Pharmacokinetics of Single Doses of VBY-376 in Healthy Adults. U.S. National Institutes of Health.
2 Hepatitis C Virus NS3/4A Protease Inhibitors: A Light at the End of the Tunnel. Viruses. 2010 August; 2(8): 1752-1765.
3 Characterization of Resistance to the Protease Inhibitor GS-9451 in Hepatitis C Virus-Infected Patients. Antimicrob Agents Chemother. 2012 October; 56(10): 5289-5295.
4 Clinical pipeline report, company report or official report of Gilead.
5 Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology. 2005 Apr;41(4):832-5.
6 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
7 Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection. J Med Chem.2014 Mar 13;57(5):1708-29.
8 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
9 Control of hepatitis C: a medicinal chemistry perspective. J Med Chem. 2005 Jan 13;48(1):1-20.
10 Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg Med Chem Lett. 2001 Jan 22;11(2):203-6.